Marinus Initiates Phase IIb Study Of Ganaxolone For Adult Partial Seizures
Marinus Pharmaceuticals announced that it is enrolling patients in an international, multi-center, placebo controlled Phase IIb study of its lead compound, Ganaxolone, as an adjunctive treatment in adults suffering from partial onset seizures.
This marks the second indication for which Marinus is evaluating Ganaxolone. Ganaxolone is also currently being evaluated in a separate Phase IIb study in infants suffering from Infantile Spasms (also called West syndrome).
"Our goal for this study is to demonstrate that Ganaxolone is a valuable addition to the therapeutic choices available for patients who continue to have seizures even when taking other anticonvulsant drugs," said Harry H. Penner, Jr., Chairman and Chief Executive Officer of Marinus. "We believe that the combination of strong evidence in the scientific literature of Ganaxolone's efficacy in epilepsy and our new proprietary formulation makes Ganaxolone a solidly viable anticonvulsant drug candidate."
Information concerning patient participation in both Marinus studies evaluating Ganaxolone can be found later in this release.